• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Valeritas touts real-world V-Go data

Valeritas touts real-world V-Go data

May 20, 2015 By Mark Hollmer

Valeritas touts real-world V-Go data

Valeritas touted real-world data from 3 separate studies of its V-Go insulin delivery system showcasing the device’s utility and effectiveness.

V-Go is a disposable, wearable insulin delivery device designed to deliver a preset dosage continually over 24 hours and on-demand doses during meals.

The 1st study looked at 153 patients and how they fared switching to the V-Go system from either multiple daily insulin injections, long-acting basal insulin therapy or no treatment. Each cohort showed improvement in glycemic control on V-Go through several follow-ups, and the group that was previously on insulin injections needed less with the company’s device.

In the 2nd study, researchers looked at the safety and efficacy of V-Go in 21 patients in 2 groups. Some were adults with latent autoimmune diabetes and others had Type I diabetes. Both experienced elevated blood glucose levels and had been treated with the standard of care – multiple daily insulin injections. Patients in both arms of the study experienced big reductions in blood glucose levels and lower insulin requirements, Valeritas said.

For the 3rd study, researchers gathered data from 2 patients over age 65 who had poorly controlled Type II diabetes. They switched from daily insulin injections to V-Go and showed improved glycemic control with lower daily insulin needs.

"In each analysis, there was a statistically significant reduction in [blood glucose levels] and lowering of daily insulin needs," Valeritas CEO Kristine Peterson said in prepared remarks. "We are also particularly encouraged since these data are shown in a real-world setting."

In March, Valeritas tabled plans for a $75 million initial public offering.

Filed Under: News Well Tagged With: Clinical Trials, Valeritas

More recent news

  • A new way to monitor glucose: Glucotrack explains 3-year CBGM implant technology
  • Dexcom continues advances in AI for CGM, type 2 diabetes awareness
  • Tandem continues to deliver more options, benefits for those with diabetes
  • Breaking: Sequel to launch twiist automated insulin delivery system next month
  • Dexcom shares U.S. report on CGM benefits for type 2 diabetes

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy